CD19 and neoplasm: Itacitinib has been shown to significantly and dose-dependently reduce the levels of various cytokines associated with CRS in in vitro and in vivo models without significantly inhibiting the proliferation and anti-tumor activity of multiple CAR-Ts (CD19/EGFR/GD2) [98].